Abstract
Breast cancer survivors are at risk of bone loss due to hormonal treatment. We conducted a case note audit to investigate patterns of care and adherence to guidelines for initial management of risk of bone loss in 42 women receiving hormonal therapy. All those receiving aromatase inhibitors (n = 14) and 10 on tamoxifen had a bone density assessment. Eleven (26%) women had osteopenia and four (9.5%) osteoporosis. Management was variable and not always aligned with the guidelines.
Original language | English |
---|---|
Pages (from-to) | 1182-1185 |
Number of pages | 4 |
Journal | Internal Medicine Journal |
Volume | 45 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2015 |
Keywords
- Aromatase inhibitors
- Bone
- Breast cancer
- Osteoporosis